2024 was a year of growth, connection, and education for dermatology NPs, PAs, and providers everywhere. From live events to digital learning, we’ve been proud to support your journey and advance patient care together. We’re so grateful to all who made this year possible—our attendees, partners, and faculty. Let’s make 2025 another year of growth, learning, and advancement together. Stay connected and we'll see you in the New Year!
Dermatology Education Foundation
Higher Education
Montclair, NJ 890 followers
The premier industry resource for NP & PA education & case-based training
About us
The DEF, a non-profit 501 (c)(3) corporation, was founded to inspire dermatology nurse practitioners (NPs) and physician assistants (PAs) to achieve a professional balance between the art of healing, the power of diagnostic skills, and case-based assessment and training. In addition to web-based content with a practical focus on www.DermNPPA.org, the DEF has created national and regional educational CME conferences designed to enhance diagnostic skills for NPs and PAs in the practice treating skin conditions and diseases.
- Website
-
https://dermnppa.org/
External link for Dermatology Education Foundation
- Industry
- Higher Education
- Company size
- 1 employee
- Headquarters
- Montclair, NJ
- Type
- Nonprofit
- Founded
- 2013
- Specialties
- dermatology
Locations
-
Primary
Get directions
c/o Physician Resources, LLC
201 Claremont Avenue
Montclair, NJ 07042, US
Employees at Dermatology Education Foundation
Updates
-
Did you know atopic dermatitis (AD) affects 1 in 10 adults in the U.S., yet it often goes undiagnosed? At the DEF Biologic & Small Molecule Bootcamp, DEF President Joe Gorelick shared key insights: ✅ AD disproportionately affects patients with darker skin tones. ✅ Accurate baseline assessments (IGA score, BSA, itch scale) are critical to track progress and optimize treatments. ✅ Face, neck, hands, feet, and genital involvement may elevate severity and expand therapeutic options. Biologics and JAK inhibitors now lead the way as FDA-approved treatments for moderate-to-severe AD. Read more on the DEF blog.
-
-
Cosibelimab-ipdl (Unloxcyt) has received FDA approval for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or radiation. This PD-L1 blocking antibody demonstrated impressive clinical trial results, with an objective response rate (ORR) of 47% and durable responses offering new hope for patients. Stay informed on the latest advancements in dermatology—read more on the DEF blog! 🩺
-
-
Johnson & Johnson is seeking FDA approval for Tremfya® (guselkumab) to treat pediatric patients with moderate-to-severe plaque psoriasis (ages 6+) and active juvenile psoriatic arthritis (ages 5+). Backed by Phase 3 data, Tremfya targets IL-23, a key driver of immune-mediated diseases. Stay tuned for updates!
-
-
Join us for the Dermalorian™ Webinar: Atopic Dermatitis CME Series On December 5th with brad glick, DO, MPH, FAAD. 📅 December 5th, 8–9 PM ET 💻 Free & CME Accredited Register Now: https://lnkd.in/ehfK9c_G
-
-
Thank you to everyone who joined us for yesterday’s Bootcamp, where we learned from our amazing faculty by reviewing real cases of vitiligo, alopecia areata, psoriasis, HS, and more! Special thanks to our sponsors for supporting the DEF Biologic & Small Molecule CME Bootcamp Series in 2024. Details on 2025 programs coming soon!!
-
-
Thank you myDermRecruiter for highlighting the Dermalorian Podcast in your list! Wishing everyone a Happy Thanksgiving and some enjoyable listening this week!
Need something to listen to while traveling this week? Here are some favorite dermatology podcasts you should definitely tune in to... ✨ Derms and Conditions: https://buff.ly/3Z6PWJj Offered by Dermsquared and hosted by James Q. Del Rosso, DO ✨ The Dermalorian Podcast: https://buff.ly/3Z6iItu Offered by the Dermatology Education Foundation ✨ Derm Club Podcast Hosted by Dr. Hannah Kopelman ✨ Cutaneous Miscellaneous Podcast: https://buff.ly/4fIxgq9 Offered by Dermsquared and hosted by Nicholas D. Brownstone, MD ✨ That's Derm Good Podcast: https://buff.ly/415uQNR Hosted by Janelle Ball ✨ The Business of Aesthetics Podcast: https://buff.ly/4fy0kAF ✨ JAMA Dermatology Author Interviews Podcast: https://buff.ly/3Z5fiHj Offered by JAMA Dermatology What are your go-to dermatology podcasts? Tell us in the comments! · · · #myDermRecruiter #Dermatology #DermatologyPodcast #DermatologyPodasts #Dermatologist #DermatologyNP #DermatologyPA #DermLife #DermListens #DermatologyCME
-
Don't miss the last Biologic & Small Molecule NP/PA CME Bootcamp Series of 2024! Join us virtually on December 1st from 1:00 pm – 4:00 pm ET for an afternoon of expert-led education designed for dermatology healthcare professionals. Register now: https://lnkd.in/e7K5jagY
-
🚨 TONIGHT! Join us for the Dermalorian™ Webinar: Atopic Dermatitis CME Series 📅 8–9 PM ET 💻 Free & CME Accredited Don't miss expert insights into atopic dermatitis treatment. Register for FREE! https://lnkd.in/gamjY7Af
-
-
Bimzelx® (bimekizumab-bkzx) is now FDA approved for moderate-to-severe hidradenitis suppurativa (HS). This IL-17F/IL-17A inhibitor showed impressive results in Phase 3 trials, hitting key endpoints and maintaining responses through 48 weeks. Learn more on the DEF blog, and join us for the FREE Virtual BootCamp on Dec. 1 to dive deeper!
-